Sidar ÇOPUR, Asiye KANBAY, Barış AFŞAR, Rengin ELSÜRER AFŞAR, Mehmet KANBAY

Pathological features of COVID-19 infection from biopsy and autopsy series

Novel coronavirus disease 2019 (COVID-19) which is caused by severe acuterespiratory syndrome corona virus 2 (SARS-CoV-2) was first identified inDecember 2019 in Chinese town Wuhan and considered as a pandemic byWorld Health Organization. The disease has variety of symptoms includingfever, shortness of breath, cough, fatigue, loss of smell and taste and diarrhea.While the majority of cases have mild symptoms, some progress to viral pneumonia, multi-organ failure, or cytokine storm and mortality is mostly causedby hypoxemic respiratory failure. Until now, more than 3.5 million peopleworldwide were infected and more than 240.000 mortality has beenoccurred. Thus, there is now evidence the disease may affect variety of organsaccording to accumulating biopsy and autopsy studies. Such pathologicalstudies have potential role on the understanding of clinical outcomes and inthe development of novel targeted therapeutic approaches. Given these aforementioned data, in the current manuscript we have summarized the pathological features of COVID-19 derived from biopsy and autopsy series.

COVID-19 infeksiyonunun otopsi ve biyopsi raporlarına göre patolojik özellikleri

Yeni koronavirüs 2019 hastalığı (COVID-19) akut respiratuvar sendromu korona virüs 2 (SARS-COV-2) ilk olarak Çin’in Wuhan şehrinde aralık 2019 tarihinde saptanmış olup, dünya sağlık örgütü tarafından pandemi olarak kabul edilmiştir. COVID-19 infeksiyonu ateş, nefes darlığı, öksürük, halsizlik, ishal, koku ve tat alma bozukluğu gibi şikayetlere neden olabilmektedir. Hastalık yüksek oranda asemptomatik geçirilse bile bazı hastalarda viral pnömoni, solunum yetmezliği, çoklu organ yetmezliği ve sitokin fırtınası gelişebilmekte ve ölüme neden olabilmektedir. Şimdiye kadar 3.5 milyonun üzerinde insan enfekte olmuş olup, 240.000 üzerinde insan ölmüştür. Biyopsi ve otopsi raporlarında akciğer dışı birçok organında tutulduğu gösterilmiştir. Bu bilgilerin yeni tedavi modalitelerinin gelişmesine yardımcı olabileceği ümit edilmektedir. Bu derlemede COVID-19 infeksiyonu olan hastalarda yapılmış biyopsi ve otopsi raporlarında covid enfeksiyonuna bağlı organ tutulumları ve tipleri detaylıca tartışılmıştır

PDF

___

1. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4).

2. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020.

3. Rodriguez-Morales AJ, Cardona-Ospina JA, GutierrezOcampo E, Villamizar-Pena R, Holguin-Rivera Y, EscaleraAntezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease 2020;101623.

4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020.

5. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology 2020.

6. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARSCoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine 2020;1-5.

7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine 2020;1-3.

8. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM) 2020;1(ahead-of-print).

9. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2020.

10. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Journal of Biological Chemistry 2020;jbc. RA120.013679.

11. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends in Pharmacological Sciences 2004;25(6):291-4.

12. Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in COVID‐19: evaluating the evidence. Clinical Pharmacology & Therapeutics 2020.

13. Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. Current Cardiology Reports 2020;22:1-4.

14. Danser AJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;HYPERTENSIONAHA. 120.15082.

15. Rodriguez-Morales AJ, Cardona-Ospina JA, GutierrezOcampo E, Villamizar-Pena R, Holguin-Rivera Y, EscaleraAntezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020;101623.

16. Zhang C, Wu Z, Li JW, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020:105954.

17. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clinical Drug Investigation 2020:1-8.

18. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020;250:117583.

19. Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, et al. CAR T Cell Therapy During the COVID-19 Pandemic. Biology of Blood and Marrow Transplantation 2020.

20. AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. International Immunopharmacology 2020:106455.

21. Chiappelli F, Khakshooy A, Greenberg G. COVID-19 immunopathology and immunotherapy. Bioinformation 2020;16(3):219.

22. Solaimanzadeh I. Acetazolamide, Nifedipine and phosphodiesterase inhibitors: rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (COVID-19). Cureus 2020;12(3):e7343.

23. Aghagoli G, Gallo Marin B, Soliman LB, Sellke FW. Cardiac involvement in COVID‐19 patients: Risk factors, predictors, and complications: A review. Journal of Cardiac Surgery 2020.

24. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology 2020;17(5):259-60.

25. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020.

26. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Medical Journal 2020.

27. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences 2020;63(3):364-74.

28. Welt FG, Shah PB, Aronow HD, Bortnick AE, Henry TD, Sherwood MW, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC’s Interventional Council and SCAI. J Am Coll Cardiol 2020.

29. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368.

30. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018;378(4):345-53.

31. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020.

32. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J 2020.

33. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology: Cardiothoracic Imaging 2020;2(2):e200067.

34. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020.

35. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis 2020.

36. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38.

37. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and Early Prognosis in Patients with COVID- 19 Pneumonia. Journal of the American Society of Nephrology 2020.

38. Peleg Y, Kudose S, D'Agati V, Siddall E, Ahmad S, Kisselev S, et al. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep 2020.

39. Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report. Iran J Kidney Dis 2020;14(3):239-42.

40. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020;51(9):843- 51.

41. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020.

42. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395(10223):507-13.

43. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368.

44. Fang D, Ma J, Guan J, Wang M, Song Y, Tian D. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study. Chin J Dig 2020;40(2020‐02‐23).

45. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology 2020.

46. Uhlen M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science 2015;347(6220):1260419.

47. Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. Journal of Clinical and Translational Hepatology 2020;8(1):13.

48. Chen H DQ. Potential natural compounds for preventing 2019-nCoV infection. 2020(Preprint).

49. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol 2020;8(1):18-24.

50. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020.

51. Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID-19: a french observational study. J Eur Acad Dermatol Venereol 2020.

52. Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with Coronavirus Disease 2019 ? J Eur Acad Dermatol Venereol 2020.

53. Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jimenez-Cauhe J. Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol 2020.

54. Estébanez A, Pérez-Santiago L, Silva E, Guillen-Climent S, García-Vázquez A, Ramón MD. Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol 2020.

55. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708-20.

56. Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol 2020.

57. Arora G, Kassir M, Jafferany M, Galadari H, Lotti T, Satolli F, et al. The COVID-19 outbreak and rheumatologic skin diseases. Dermatol Ther 2020:e13357.

58. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID- 19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020;15(5):700-4.

59. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020;49(0):E009.

60. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020;8(4):420-2.

61. Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol 2020.

62. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020.

63. Luo W YH, Gou J, Li X, Sun Y, Li J, Liu L. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). 2020(Preprint).

64. Karami P, Naghavi M, Feyzi A, Aghamohammadi M, Novin MS, Mobaien A, et al. Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings. Travel Med Infect Dis 2020:101665.

65. Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi 2020;36(1):21-3.

66. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. medRxiv 2020.

67. Konopka KE, Wilson A, Myers JL. Postmortem Lung Findings in an Asthmatic with Coronavirus Disease 2019 (COVID-19). Chest 2020.

68. Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and Ultrastructural Findings of Fatal COVID-19 Infections. medRxiv 2020.

69. Liu Q, Wang R, Qu G, Wang Y, Liu P, Zhu Y, et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi 2020;36(1):21.

70. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020.

71. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal involvement and early prognosis in patients with COVID- 19 pneumonia. J Am Soc Nephrol 2020.

72. Xu X, Chang XN, Pan HX, Su H, Huang B, Yang M, et al. [Pathological changes of the spleen in ten patients with new coronavirus infection by minimally invasive autopsies]. Zhonghua Bing Li Xue Za Zhi 2020;49(0):E014.

73. Zengarini C, Orioni G, Cascavilla A, Horna Solera C, Fulgaro C, Misciali C, et al. Histological pattern in Covid- 19 induced viral rash. J Eur Acad Dermatol Venereol 2020.

74. Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020.

75. Ahouach B, Harant S, Ullmer A, Martres P, Bégon E, Blum L, et al. Cutaneous lesions in a patient with COVID-19: are they related? Br J Dermatol 2020.

76. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020.